JP2017531044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531044A5 JP2017531044A5 JP2017539528A JP2017539528A JP2017531044A5 JP 2017531044 A5 JP2017531044 A5 JP 2017531044A5 JP 2017539528 A JP2017539528 A JP 2017539528A JP 2017539528 A JP2017539528 A JP 2017539528A JP 2017531044 A5 JP2017531044 A5 JP 2017531044A5
- Authority
- JP
- Japan
- Prior art keywords
- varenicline
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical formulation
- micrograms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 54
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 26
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims description 24
- 229960004751 varenicline Drugs 0.000 claims description 24
- 210000003928 nasal cavity Anatomy 0.000 claims description 21
- 102000003923 Protein Kinase C Human genes 0.000 claims description 15
- 108090000315 Protein Kinase C Proteins 0.000 claims description 15
- 238000011200 topical administration Methods 0.000 claims description 12
- 102000001253 Protein Kinase Human genes 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 108060006633 protein kinase Proteins 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 9
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 8
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 8
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims description 5
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- 241000021559 Dicerandra Species 0.000 claims description 5
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 238000000586 desensitisation Methods 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 5
- 229960005330 pimecrolimus Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229940098458 powder spray Drugs 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 229960001967 tacrolimus Drugs 0.000 claims description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 5
- 239000006200 vaporizer Substances 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 230000004489 tear production Effects 0.000 claims description 4
- 206010052143 Ocular discomfort Diseases 0.000 claims description 3
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000011514 reflex Effects 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 210000003901 trigeminal nerve Anatomy 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 38
- 239000000556 agonist Substances 0.000 description 9
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 3
- MBQYQLWSBRANKQ-IMTBSYHQSA-N (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane Chemical compound N1=C(Cl)C(Cl)=CC(N2C[C@H]3NC[C@H]3C2)=C1 MBQYQLWSBRANKQ-IMTBSYHQSA-N 0.000 description 3
- LVGMMVAWLISWJD-MRVPVSSYSA-N (3r)-1-pyridin-3-ylpyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1C1=CC=CN=C1 LVGMMVAWLISWJD-MRVPVSSYSA-N 0.000 description 3
- USXYDBGSWSSTGE-UHFFFAOYSA-N 3-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound N1=NC(Cl)=CC=C1N1CC(N2)CCC2C1 USXYDBGSWSSTGE-UHFFFAOYSA-N 0.000 description 3
- XKFMBGWHHBCWCD-QMMMGPOBSA-N 3-[[(2s)-azetidin-2-yl]methoxy]pyridine Chemical compound C([C@H]1NCC1)OC1=CC=CN=C1 XKFMBGWHHBCWCD-QMMMGPOBSA-N 0.000 description 3
- GPXAWLDGWSBLKM-MWLCHTKSSA-N 5-[(1r,5s)-3,6-diazabicyclo[3.2.0]heptan-6-yl]pyridine-3-carbonitrile Chemical compound N#CC1=CN=CC(N2[C@@H]3CNC[C@@H]3C2)=C1 GPXAWLDGWSBLKM-MWLCHTKSSA-N 0.000 description 3
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 3
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 description 3
- WECKJONDRAUFDD-ZDUSSCGKSA-N N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 WECKJONDRAUFDD-ZDUSSCGKSA-N 0.000 description 3
- IPKZCLGGYKRDES-ZDUSSCGKSA-N Pha-543613 Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-ZDUSSCGKSA-N 0.000 description 3
- PEAMDZVDNYENPN-UHFFFAOYSA-N [2-(4-fluoroanilino)-4-methyl-1,3-thiazol-5-yl]-thiophen-3-ylmethanone Chemical compound S1C(C(=O)C2=CSC=C2)=C(C)N=C1NC1=CC=C(F)C=C1 PEAMDZVDNYENPN-UHFFFAOYSA-N 0.000 description 3
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 3
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 3
- 229940027564 cytisine Drugs 0.000 description 3
- 229930017327 cytisine Natural products 0.000 description 3
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 3
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 3
- LEXDAVFCJPDCNA-VNTMZGSJSA-N molport-035-765-978 Chemical compound C1([C@@H](C2)C3)=CC=CC(=O)N1C[C@@H]3CN2CCN(C1)C[C@@H]2C[C@H]1C1=CC=CC(=O)N1C2 LEXDAVFCJPDCNA-VNTMZGSJSA-N 0.000 description 3
- -1 tevanicline Chemical compound 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US62/066,280 | 2014-10-20 | ||
| US201562100844P | 2015-01-07 | 2015-01-07 | |
| US62/100,844 | 2015-01-07 | ||
| PCT/US2015/056273 WO2016064759A1 (en) | 2014-10-20 | 2015-10-19 | Methods of treating ocular conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020193269A Division JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531044A JP2017531044A (ja) | 2017-10-19 |
| JP2017531044A5 true JP2017531044A5 (enExample) | 2018-11-29 |
| JP6873906B2 JP6873906B2 (ja) | 2021-05-19 |
Family
ID=55748136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
| JP2020193269A Active JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020193269A Active JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (14) | US9532944B2 (enExample) |
| EP (3) | EP4413974A3 (enExample) |
| JP (3) | JP6873906B2 (enExample) |
| KR (2) | KR102511955B1 (enExample) |
| CN (3) | CN107106542B (enExample) |
| AU (2) | AU2015336216B2 (enExample) |
| BR (2) | BR112017008097B1 (enExample) |
| CA (1) | CA2965129C (enExample) |
| DK (2) | DK3848028T5 (enExample) |
| EA (1) | EA035335B1 (enExample) |
| ES (2) | ES2848977T5 (enExample) |
| FI (1) | FI3848028T3 (enExample) |
| IL (3) | IL318427A (enExample) |
| MX (2) | MX392383B (enExample) |
| MY (1) | MY186870A (enExample) |
| PH (1) | PH12017500602A1 (enExample) |
| PL (1) | PL3848028T3 (enExample) |
| PT (2) | PT3209295T (enExample) |
| SG (2) | SG10202011669PA (enExample) |
| WO (1) | WO2016064759A1 (enExample) |
| ZA (1) | ZA201703467B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4413974A3 (en) | 2014-10-20 | 2024-10-09 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| KR102512777B1 (ko) * | 2016-04-07 | 2023-03-23 | 오이스터 포인트 파마 인코포레이티드 | 안구 장애의 치료 방법 |
| TW202019424A (zh) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| CN112638364A (zh) | 2018-07-10 | 2021-04-09 | 奥伊斯特普安生物制药公司 | 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合 |
| TW202206078A (zh) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染 |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| DE102023208057A1 (de) * | 2023-08-23 | 2025-02-27 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| DE60209929T2 (de) | 2001-11-29 | 2006-11-16 | Pfizer Products Inc., Groton | Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen |
| AU2003269413A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| WO2006040680A1 (en) * | 2004-10-15 | 2006-04-20 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| DK1809238T3 (da) * | 2004-11-09 | 2010-01-25 | Novagali Pharma Sa | Ophthalmiske emulsioner indeholdende et immunosuppressivt middel |
| WO2006100075A2 (en) * | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| US20070054843A1 (en) | 2005-08-26 | 2007-03-08 | Yeomans David C | Methods for treatment of headaches by administration of oxytocin |
| CA2949643C (en) | 2005-09-27 | 2018-05-15 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| TWI404532B (zh) | 2006-11-02 | 2013-08-11 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| AU2008211613B2 (en) * | 2007-02-02 | 2013-05-23 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| MX2010009727A (es) | 2008-03-05 | 2010-09-28 | Targacept Inc | Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos. |
| CN102143963A (zh) | 2008-09-05 | 2011-08-03 | 塔加西普特公司 | 二氮杂双环辛烷的酰胺及其应用 |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| MX2011005611A (es) | 2008-12-01 | 2011-09-15 | Targacept Inc | Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina. |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| CA2841416A1 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| BR112013032044A2 (pt) * | 2011-06-30 | 2016-12-13 | Toray Industries | antiprurítico |
| CN103930112B (zh) * | 2011-10-20 | 2018-11-09 | 诺华股份有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂疗法的响应的生物标志物 |
| WO2013080196A1 (en) * | 2011-11-30 | 2013-06-06 | D.E.S. Diagnostics Ltd. | Dry eye diagnostic |
| ES2426517B1 (es) * | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| PT2968368T (pt) | 2013-03-15 | 2017-11-15 | Glia Llc | Administração craniana de substâncias farmacêuticas |
| EP2986339A4 (en) | 2013-04-19 | 2016-12-21 | Oculeve Inc | Nasal stimulation devices and methods |
| EP4413974A3 (en) | 2014-10-20 | 2024-10-09 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| KR102512777B1 (ko) | 2016-04-07 | 2023-03-23 | 오이스터 포인트 파마 인코포레이티드 | 안구 장애의 치료 방법 |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| CN112638364A (zh) | 2018-07-10 | 2021-04-09 | 奥伊斯特普安生物制药公司 | 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合 |
-
2015
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/zh active Active
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/da active
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/da active
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/pt active IP Right Grant
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 PT PT158523407T patent/PT3209295T/pt unknown
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/zh active Active
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 PT PT202125563T patent/PT3848028T/pt unknown
- 2015-10-19 EA EA201790893A patent/EA035335B1/ru unknown
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/zh active Active
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/ja active Active
- 2015-10-19 ES ES15852340T patent/ES2848977T5/es active Active
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 MX MX2017005064A patent/MX392383B/es unknown
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/pl unknown
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/fi active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/ko active Active
- 2015-10-19 ES ES20212556T patent/ES2986830T3/es active Active
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/ko active Active
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/pt active IP Right Grant
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/es unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/ja active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/ja active Active
-
2023
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
-
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
-
2025
- 2025-04-03 US US19/169,843 patent/US20250255865A1/en active Pending
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en active Pending
- 2025-04-03 US US19/169,836 patent/US20250275963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531044A5 (enExample) | ||
| JP7492548B2 (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
| EP3372229B1 (en) | Methods of increasing tonic inhibition and treating angelman syndrome | |
| IL293188A (en) | Varnicline compound for use as a drug for treating dry eye, increasing tear production and treating eye discomfort and a premebactet preparation containing Varnicline | |
| JP2008044951A5 (enExample) | ||
| JP2017509684A5 (enExample) | ||
| JP2019513759A5 (enExample) | ||
| WO2018089709A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| RU2012131251A (ru) | Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз | |
| JP2017534604A5 (enExample) | ||
| JP2021038250A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| RS60554B1 (sr) | Intranazalna kompozicija koja sadrži betahistin | |
| US11414459B2 (en) | Metabolite inspired selective oxytocin receptor agonists | |
| JPWO2020247127A5 (enExample) | ||
| US20220184052A1 (en) | Composition comprising fexofenadine | |
| WO2022123511A1 (en) | A composition comprising fexofenadine | |
| JP2015519332A (ja) | 鼻腔適用のための組成物 | |
| US20240408003A1 (en) | Compositions, devices and methods for the treatment of alcohol use disorder | |
| NZ785093B2 (en) | Methods of treating ocular conditions | |
| HK1260775B (en) | Methods of increasing tonic inhibition and treating angelman syndrome | |
| TH128834A (th) | วิธีการสำหรับการใช้วาโซเพรสซินแอนทาโกนิสต์กับตัวกระทำเคมีบำบัดแอนธราไซคลีนเพื่อลดสภาพเป็นพิษต่อหัวใจ และ/หรือการปรับปรุงการรอดชีวิต | |
| NZ783506B2 (en) | Therapeutic compounds | |
| UA110204C2 (uk) | Фармацевтична композиція 1-адамантилетилокси-3-морфоліно-2-пропанолу або його фармацевтично прийнятних солей як нейроретинопротекторний лікарський засіб | |
| UA88482U (uk) | Застосування фармацевтичної композиції 1-адамантилетилокси-3-морфоліно-2-пропанолу або його фармацевтично прийнятних солей як нейроретинопротекторного лікарського засобу |